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Do markers of eosinophil activation differ in their ability to detect subjects with atopy or bronchial 
hyper-responsiveness (BHR)? Comparisons of serum levels of eosinophil peroxidase (S-EPO), of eosinophil 
cationic protein (S-ECP) and the blood eosinophil count (B-Eos) have been made between 154 subjects aged 
2044 years, participating in the European Community Respiratory Health Survey in Uppsala, Sweden. 
Subjects with atopy had significantly higher levels of S-EPO and S-ECP than those without atopy 
(P<O.OOl). Subjects with BHR had significantly higher levels of S-EPO (P<O.OOl) and B-Eos (P<O.Ol) than 
subjects without BHR. Persons reporting asthma-related symptoms had significantly higher levels of S-EPO 
and B-Eos than subjects without such symptoms (P<O.OOl and PcO.01, respectively). Asthma symptom score 
correlated significantly to S-EPO (r=0.26, P<O.Ol), S-ECP (r=0.20, PcO.05) and B-Eos (r=O.lS, P40.05). 
Finally, S-EPO was significantly more sensitive than S-ECP for detecting subjects with BHR (PcO.05) and 
significantly more sensitive than B-Eos for detecting both subjects with BHR and subjects with a combination 
of atopy and BHR (PcO.05). 
It is concluded that S-EPO is a promising marker with a higher sensitivity for BHR than S-ECP or B-Eos. 
Further studies are needed to define the value of S-EPO when following disease activity. 
Introduction 
Concepts on the pathogenesis of asthma have 
changed. Asthma is now thought of as a syndrome 
characterized by an intermittent and reversible air- 
flow obstruction superimposed on a background of 
inflammation. Still, our means of monitoring asthma 
activity are largely confined to measurements of the 
physiological manifestations such as bronchial hyper- 
responsiveness (BHR). A reliable marker of airway 
inflammation is therefore needed. 
It has become apparent that the eosinophil leuco- 
cyte is intimately involved in the pathogenesis of 
asthma and, at least partly, responsible for the late 
asthma reaction which is thought to reflect the airway 
inflammatory response (1). The eosinophil can, upon 
activation, release a number of proteins which are 
thought to be of major importance for the inflamma- 
tory potential of the cell (2). These include, among 
others, the eosinophil cationic protein and the eosi- 
nophil peroxidase. Both the total eosinophil count in 
peripheral blood (B-Eos) (3,4) and serum levels of the 
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eosinophil cationic protein (S-ECP) (5-7) have been 
shown to correlate to disease activity in asthma 
whether measured in terms of symptoms or h.u$ 
function parameters. For the purpose of monitoring 
asthma therapy, S-ECP seems superior to B-Eos 
in that it shows a closer relationship to objective 
findings (8, 9) and responds earlier to therapy (10). 
That pre-treatment with inhaled glucocortico- 
steroids abolishes the late asthma reaction, and 
normalizes S-ECP but not the eosinophil count (5), 
implies that degranulation is a prerequisite for the 
eosinophil-induced inflammation. Eosinophils from 
asthmatic patients also have an increased tendency to 
degranulate upon stimulation suggesting in vivo prim- 
ing (11). The pathophysiologic secretogogue of the 
eosinophil is not known, however, and there is evi- 
dence that degranulation may be selective as to the 
protein contents of the granules (12). In this way the 
eosinophil may have a secretion profile specific for 
the allergic response. Apart from the pathogenetic 
role this may have, knowledge of the eosinophil 
secretion profile may be of value when monitoring 
asthma activity and therapy. In vitro stimulation of 
the eosinophil with anti-IgE-monoclonal antibodies 
(MAb) was shown to result in a preferential release of 
EPO (13). Should this occur in vivo as well, then 
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S-EPO may be a useful marker in allergic disease. 
This is supported by the finding that EPO secretion is 
relatively insensitive to bacterial infections, contrary 
to ECP secretion (14). 
The aim of the present study was to assess the 
value of S-EPO as a marker of atopy and BHR in the 
general population, to compare S-EPO in individuals 
with and without atopy, and to correlate S-EPO to 
S-ECP and B-Eos. 
Materials and Methods 
STUDY POPULATION 
An extensive study on the prevalences of allergy 
and asthma is now being conducted in 48 centres in 
23 countries throughout Europe and in other parts 
of the world as part of the European Community 
Respiratory Health Survey (15). Each centre has 
clear geographic and administrative boundaries and 
a total population of at least 150 000. Sweden con- 
tributes with data from three such centres, one of 
which is Uppsala. In December 1990, a questionnaire 
on asthma-related symptoms was mailed to 3600 
persons, men and women, aged 2044 years, ran- 
domly selected from the population register in the 
municipality of Uppsala. From this cohort, a random 
sample of 800 was selected for further investigation. 
Additionally, all persons from the main sample, 
reporting use of asthma medication, attacks of 
asthma or awakening because of shortness of breath, 
were invited to participate. A total of 1016 persons 
were thus invited, but the full protocol was carried 
out on 699. These 699 subjects were examined for 
signs of allergy and BHR, with skin prick tests for 10 
allergens and a bronchial provocation test with 
methacholine. They were all interviewed and exam- 
ined by specially trained nurses. This part of the 
study was conducted during the period from April 
1991 to February 1992. The investigations took place 
from 8.00 a.m. to 17.00 p.m. each day. The procedure 
took about 2 h for each person to complete. The 
same investigation sequence was applied to all 
persons. The blood was drawn just prior to the 
methacholine provocation test. 
For the S-EPO analysis 50 individuals were ran- 
domly chosen from each of four diagnostic categories 
according to the classification described below. All 
persons gave their informed consent. The protocol of 
the study was approved by the Ethics Committee of 
the Medical Faculty of Uppsala University. 
SKIN PRICK TESTS 
Skin prick tests were carried out in a carefully 
standardized way, by use of allergen-coated lancets 
(Phazet@, Pharmacia Diagnostics, Uppsala, Sweden). 
The following allergens were used: D. pteronyssinus; 
cat; birch; dog; Cladosporium; olive; ragweed; 
mugwort; timothy; and Alternaria with histamine as 
a positive control. Subjects with dermatographism 
were excluded. 
LUNG FUNCTION AND BRONCHIAL PROVOCATION 
Forced expiratory volume in 1 s (FEV,) was 
measured using the Spiro Medics computerized dry- 
rolling seal spirometer system 2130 (Sensor Medics, 
Anaheim, California, U.S.A.). The predicted values 
were calculated for each patient (16). Peak expiratory 
flow (best of three measurements) was recorded twice 
daily during 1 week with a mini-Wright peak flow 
meter (Clement Clarke, London, U.K.). Peak flow 
variability was calculated by dividing the difference 
between the highest and lowest daily PEF reading by 
the daily mean PEF value (17). In the bronchial 
provocation test, methacholine was delivered in a 
stepwise fashion by a MEFAR inhalation dosimeter 
(18) up to 2 mg of methacholine, or until FEV, had 
decreased by 20% or more. 
BLOOD SAMPLES 
From each volunteer the following venous blood 
samples were collected: 
(i) Five millilitres supplemented with EDTA 
(3,4 mmol 1 - ‘), which was used for analysis of blood 
eosinophil count on a Technichon H*l(Technicon 
Chemicals Company, Tournai, Belgium). 
(ii) Ten millilitres from which serum was collected 
and analysed for total serum immunoglobulin E 
(S-IgE) and specific IgE for D. pteronyssinus, cat, 
birch, Cladosporium and timothy. 
(iii) Twenty millilitres of whole blood which was 
allowed to coagulate for 60 min in room temperature 
and then centrifugated. Serum was then collected and 
kept frozen at - 70°C until analysed for ECP and 
EPO. The concentration of S-ECP was assayed by 
means of a double antibody radioimmunoassay 
(KabiPharmacia Diagnostics AB, Uppsala, Sweden). 
The intra- and interassay coefficients of variation are 
less than 1 l%, and the detection limit is less than 
2pg1-’ (19). 
(iv) The concentration of S-EPO was assayed with 
a solid phase immunoradiometric test based on two 
EPO specific monoclonal antibodies. Briefly, in the 
assay samples were incubated in plastic tubes (star 
tube, Nun@ Denmark) coated with anti-EPO anti- 
body. After an overnight incubation, the tubes were 
washed three times with saline and ?abelled, anti- 
EPO antibody was added. After an additional 4-h 
incubation, the tubes were washed three times with 
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saline and the remaining radioactivity was deter- 
mined. The data was evaluated against a EPO stan- 
dard ranging from 0.5 pug 1 - ’ to 200 pug 1 - i. The 
precision between assays (coefficient of variation) was 
less than 10%. 
QUESTIONNAIRE 
The questionnaire used was a modified version of 
the IUATLD questionnaire (20,21). It contained a 
total of 71 questions concerning airway symptoms, 
housing, social situation, education, environmental 
exposure during childhood, etc. All questions were 
translated into Swedish and then back to English in 
order to minimize translation bias. The structure of 
the questionnaire was such as to reflect the period 
prevalence of airway symptoms (symptoms in the last 
12 months) as opposed to point, or cumulative 
prevalence. 
CLASSIFICATIONS 
On the basis of the methacholine test and the skin 
prick tests, the subjects were classified into four 
diagnostic categories: 
H, Healthy controls, with no BHR and no atopy; 
B, persons with BHR but no atopy; 
A, persons with atopy but no BHR; 
AB, persons with BHR and atopy. 
For this classification the following definitions 
were used: 
(i) BHR was defined as a positive methacholine 
test, i.e. a reduction in FEV, by at least 20% after 
inhalation of 2 mg or less of methacholine. 
(ii) Atopy was defined as: (a) a prick test reaction 
to at least one of the above mentioned allergens 
with a mean diameter 2 3 mm; and (b) no dermatog- 
raphism (22). 
For symptom analysis, symptoms of asthma were 
defined as a positive answer to one of the following 
questions. ‘Have you at any time during the last 
12 months had: 
(i) wheezing in the chest? 
(ii) breathlessness while wheezing or wheezing 
without a cold? 
(iii) a daytime attack of breathlessness during 
exercise or while resting? 
(iv) a night-time awakening because of breathless- 
ness or tightness in the chest?. 
A positive answer to each of these questions was 
given a score of 1 point, and thus the range of 
possible symptom scores was O-4. 
STATISTICAL ANALYSIS 
Comparison between groups of subjects was made 
with unpaired t-test and ANOVA. Correlations 
Table I Characteristics of the study population (n = 154) 
n (“A) 
Atow 79 (51) 
Bronchial hyper-responsiveness 15 (49) 
Asthma symptoms 92 (60) 
Smokers 46 (30) 
Asthma medication 53 (34) 
Inhaled steroids 15 (10) 
Daily inhaled steroids 6 (4) 
Oral steroids 0 (0) 
Mean f SD Range 
FEV, (% predicted) 
PEF variability (?&) 
Total IgE 
105 f 13 73-104 
5f4 O-18 
104*226 2-2000 
between S-EPO, S-ECP, B-Eos and continuous vari- 
ables were investigated with single linear regression 
while correlation with symptom score was analysed 
with Spearman’s rank correlation test. Comparison 
on the diagnostic sensitivity and specificity of S-EPO, 
S-ECP and B-Eos was analysed with X2-test. In order 
to achieve a normal distribution, S-EPO, S-ECP and 
B-Eos were log transformed when making statisti- 
cal analyses. A P-value ~0.05 was regarded as 
statistically significant. 
Results 
Serum samples for all analyses were obtained from 
154 individuals; 70 men and 84 women (mean age 
33 years, range 2045). The characteristics of these 
subjects are presented in Table 1. S-EPO was signifi- 
cantly related to S-ECP (r=O.82) and B-Eos (r=0.65) 
(P<O.OOl) (Fig. 1). A significant correlation was also 
found between S-EPO and S-IgE (r=0.36, P<O.OOl). 
S-IgE was also significantly related to S-ECP 
(r=O.33) and B-Eos (r=0.35) (P<O.OOl). The mean, 
median and range of each variable are shown in 
Table 2. 
In subjects with atopy, significantly higher levels 
of S-EPO (18.0 * 15.5 vs. 12.7 f 12.1 pgll ‘) and 
S-ECP (18.1 & 10.1 vs. 13.8~t8.6pgl-‘) werefound 
than in those without atopy (P<O.Ol). In individuals 
with BHR, significantly higher levels of S-EPO 
(19.2 & 16.6 vs. 11.8 * 10.3pg l- ‘, P<O.OOl) and 
B-Eos (260 + 168 vs. 187 f 121 x lo6 l- ‘, PcO.01) 
were measured than in subjects with no BHR. Sig- 
nificantly higher levels of S-EPO and B-Eos were 
also found in persons who reported asthma-related 
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Fig. 1 Correlation between eosinophil peroxidase (S-EPO) 
and eosinophil cationic protein (S-ECP) in serum, and the 
blood eosinophil count (B-Eos). 
symptoms than in subjects with no such symptoms 
(l&2& 16.2 vs. 11~2f9~l,~gl-‘, WO.001 and 
249 f 167 vs. 183 k 121 x lo6 l- ‘, P<O.Ol, respec- 
tively). A significantly positive correlation between 
symptom score and S-EPO was found (~~0.26, 
WO.01). S-ECP and B-Eos were also positively 
and significantly related to symptom score (rc0.20 
and r=0.18, respectively) (P<O.O5). No significant 
relation was found between any of S-EPO, 
S-ECP, B-Eos and age, sex , smoking, FEV, or PEF 
variability. 
A comparison of S-EPO, S-ECP and B-Eos 
levels between subjects in the four previously 
described diagnostic categories is presented in Fig. 
2. In order to compare the sensitivity and specificity 
of S-EPO, S-ECP and B-Eos as markers of BHR 
and of the combination of atopy and BHR, limit 
values corresponding to the upper inter-quartile 
range of the group of healthy subjects with- 
out atopy and BHR were used. The limit values 
given according to this criteria were > 12.0,~g l- ’ 
for S-EPO, >15.o/Ug1- for S-ECP and 
>240 x lo6 l- ’ for B-Eos. The results of this com- 
parison are presented in Fig. 3. S-EPO was signifi- 
cantly more sensitive than S-ECP for detecting 
subjects with BHR (WO.05) and significantly more 
sensitive than B-Eos for detecting both subjects 
with BHR and subjects with the combination of 
atopy and BHR (PcO.05). No significant difference 
was found regarding specificity between S-EPO, 
S-ECP and B-Eos. 
Table 2 Serum levels of eosinophil peroxidase (EPO), eosinophil cationic protein (ECP) and 
blood eosinophil count (B-Eos) in four patient categories 
Mean f SD Median IQ range Range 
S-EPO 
No Atopy or BHR (n=40) 
Atopy, no BHR (n=39) 
BHR, no atopy (n = 35) 
Atopy and BHR (n=40) 
S-ECP 
10.6 f 11.2 7.2 4.5-12.0 1664.4 
13.0 f 9.2 9.7 6.4-17.1 1638.0 
15.1 * 12.8 12.0 5.8819.7 1.7759.4 
22.8 f 18.7 17.2 11.6-29.2 1982.9 
No Atopy or BHR (n=40) 
Atopy, no BHR (n=39) 
BHR, no atopy (n=35) 
Atopy and BHR (n=40) 
B-Eos 
12.4 f 7.4 10.3 7415.0 3.8839.2 
16.6 f 8.7 15.1 10.8-19.9 2.545.5 
15.3 & 9.6 12.7 8.3-19.3 3.841.1 
19.6 f 11.5 16.7 11.5526.0 3651.9 
No Atopy or BHR (n=40) 185 f 127 155 loo-238 40-670 
Atopy, no BHR (n=39) 189+ 115 168 108-230 20-580 
BHR, no atopy(n=35) 225 f 152 180 8&318 31-600 
Atopy and BHR (n=40) 291 f 177 240 155-390 50-740 
BHR, bronchial hyper-responsiveness; IQ, inter-quartile. 
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Discussion 
This analysis has studied the correlation between 
S-EPO, one of the products of the eosinophil leuco- 
cyte, and other subjective and objective findings 
related to allergic diseases and asthma in a popula- 
tion sample. The aim was to assess the value of 
S-EPO in predicting symptoms and signs of allergy 
and asthma, and to compare this to S-ECP and 
B-Eos. S-EPO was found to have a better sensitivity 
for BHR than S-ECP and B-Eos, and S-EPO was 
found to differ significantly between persons with 
BHR, with and without atopy, whereas S-ECP and 
B-Eos did not. 
The eosinophil granule proteins are cytotoxic to 
epithelial cells (23) perhaps causing the shedding of 
bronchial epithelium which is characteristic for 
asthma. Epithelial shedding has, in turn, been shown 
to be closely related to BHR, another hallmark of 
asthma (24). The eosinophil peroxidase is a highly 
basic protein, released from the eosinophil both by 
soluble stimuli and by adhesion to larger opsonized 
targets (25). It is cytotoxic to epithelial cells in the 
presence of H,O, and halide. Some studies have 
linked the infiltration of eosinophils with the increase 
in capillary permeability also seen in asthma (26) and 
Yoshikawa et al. have suggested that the EPO-halide 
system might mediate this effect (27). Finally, EPO 
has been shown to down-regulate the beta-adrenergic 
receptor density on the guinea pig lung membrane 
(28), which could be an additional mechanism by 
which EPO may influence the induction of BHR. 
This study has found significant differences in 
S-EPO and B-Eos between individuals with BHR and 
without BHR (Fig 2), but the significance was highest 
for S-EPO. S-EPO also had the highest significance 
of the three variables when related to symptom score. 
When compared to B-Eos and S-ECP, S-EPO was 
significantly more sensitive for detecting persons with 
BHR (Fig.3 ). 
The present authors have recently reported that 
S-ECP levels are not a direct reflection of the 
eosinophil count and that measuring both variables 
has an additional value in predicting asthma (6). One 
possible explanation for this is that the cell can be 
selectively activated by different stimuli, causing 
Fig. 2 Levels of eosinophil peroxidase (S-EPO) and eosi- 
nophil cationic protein (S-ECP) in serum, and the blood 
eosinophil count (B-Eos) [median and inter-quartile range 
(25-75%)] in healthy subjects without atopy and bronchial 
hyper-responsiveness (BHR) (H, n=40), subjects with atopy 
but no BHR (A, n=39), subjects with BHR but no atopy (B, 
n=35) and subjects with a combination of atopy and BHR 
(AB, n=40). *P<O.O5; **P<O.Ol; ***P<O.OOl. 
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responses appropriate for different circumstances. 
Such a selective release or activation has been sug- 
gested by other authors (11-13). The mechanism may 
involve differences in the compartmentalization of 
the proteins and/or may be linked to different signal 
transduction pathways, delivered by involved recep- 
tors (29,30). Tomassini et aZ.(13) showed that stimu- 
lating eosinophils from allergic patients with anti-IgE 
Mabs caused a release of EPO, whereas ECP was 
preferentially released by IgG stimuli. Other studies 
have shown a different secretory response to pharma- 
cological agents in W-o depending on the stimuli. 
Winqvist et al. (31) found that phagocytic stimuli 
with opsonized Sephadex particles was reduced by 
steroids while others found that immunoglobulin- 
induced degranulation was not affected by steroids 
(32). If this applies to the in vivo situation, then 
additional pharmaceutical interventions may be 
needed to fully counteract the harmful effects of the 
eosinophil granule proteins. 
In this study, there were significantly higher levels 
of both S-EPO and S-ECP in the allergic persons 
compared to the non-allergic. When limiting the 
comparison to persons with BHR, with and without 
atopy, S-EPO (but not S-ECP or B-Eos) showed 
significant differences between these two groups 
(Fig. 2). 
It is concluded that S-EPO seems to be a promising 
marker, with a higher sensitivity than S-ECP or 
B-Eos, for asthma symptoms and BHR. These data 
also lend support to the hypothesis that a differential 
secretion from eosinophil granules does take place 
with a predilection towards S-EPO in allergic disease. 
Further studies are warranted to define the value of 
S-EPO in following disease activity and response to 
therapy. 
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